Guggenheim Initiates Coverage On Zevra Therapeutics with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Guggenheim has initiated coverage on Zevra Therapeutics with a Buy rating and set a price target of $20.
October 07, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim has initiated coverage on Zevra Therapeutics with a Buy rating and a price target of $20, indicating positive sentiment and potential upside.
The initiation of coverage with a Buy rating and a specific price target by a reputable firm like Guggenheim suggests confidence in Zevra Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100